Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9158922 | 0.96 | NFKB1 (0.51) | MAPTNFKB1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL594105 | 0.94 | RAB9A (0.51) | MAPTNFKB1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL21469023 | 0.92 | MAPT (0.54) | MAPTNFKB1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL9850747 | 0.92 | MAPT (0.54) | MAPTNFKB1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL9158692 | 0.91 | MAPT (0.49) | MAPTNFKB1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL6788044 | 0.88 | ALDH1A1 (0.49) | MAPTL3MBTL1ALDH1A1KDM4ELMNA | |
| SCHEMBL9766627 | 0.86 | MAPT (0.43) | MAPTNFKB1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL9153756 | 0.85 | RARB (0.47) | MAPTNFKB1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL9157673 | 0.84 | ALDH1A1 (0.46) | MAPTL3MBTL1ALDH1A1KDM4ELMNA | |
| SCHEMBL10483978 | 0.83 | GAA (0.47) | MAPTL3MBTL1ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2704701-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2673260-A1 | GLUCAGON RECEPTOR MODULATOR | Pfizer Inc (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013063385-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012151355-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012107850-A1 | GLUCAGON RECEPTOR MODULATOR | PFIZER INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| WO-2008019240-A2 | 3, 6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| CN-100343233-C | Malononitrile compounds and their use | SUMITOMO CHEMICAL CO (JP) | 2007-10-17 | — | — | CN | disclosed |
| WO-2007044927-A2 | 6, 11-BRIDGED TRICYCLIC MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-5334724-A | Preparation of substituted 2-chloropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-02 | — | — | US | disclosed |
| EP-0438691-B1 | Process for the preparation of substituted 2-chloropyridines | BAYER AG (DE) | 1994-02-16 | — | — | EP | disclosed |
| EP-0438691-A1 | Process for the preparation of substituted 2-chloropyridines | BAYER AG (DE) | 1991-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | MAPT 4455/4885NFKB1 1805/4885L3MBTL1 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.